Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,753 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Expanded Game Squad for Neurodiverse Youth

NCT03665415
View directory record Official record
Conditions
Physical Activity, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Health Behavior, Developmental Disorder
Interventions
NDGameSquad
Behavioral
Lead sponsor
Merrimack College
Other
Eligibility
11 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Marblehead, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Study in Pancreatic Cancer Patients

NCT01693523
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants

NCT07717918
View directory record Official record
Conditions
Healthy
Interventions
BL1332 eye drops, BL1332 Placebo eye drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820
View directory record Official record
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions
INZ-701, Control Arm (Conventional Therapy)
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
1 Year to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

NCT00765882
View directory record Official record
Conditions
Chronic Constipation
Interventions
Linaclotide 290 micrograms, Linaclotide 145 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 28, 2026, 6:35 PM EDT
Recruiting Not applicable Interventional

Sleep Promotion and Pediatric Hypertension

NCT06642246
View directory record Official record
Conditions
Insufficient Sleep, Hypertension
Interventions
Intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

NCT03763149
View directory record Official record
Conditions
Advanced Malignancies
Interventions
IBI188
Biological
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Grand Rapids, Michigan • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Ambrisentan in Participants With Pulmonary Hypertension

NCT00777920
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 1 Interventional

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 1 Interventional

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

NCT01212380
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Rehabilitation in Concussion Management: A Randomized Controlled Trial

NCT02988596
View directory record Official record
Conditions
Concussion, Brain
Interventions
Multidimensional Active Rehabilitation, Enhanced Graded Exertion
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 99 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Durham, North Carolina • Elon, North Carolina • Hillsborough, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 28, 2026, 6:35 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

NCT00832520
View directory record Official record
Conditions
Advanced Cancer
Interventions
Remeron (mirtazapine)
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 28, 2026, 6:35 PM EDT
Active, not recruiting Phase 1 Interventional

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217
View directory record Official record
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Not applicable Interventional Results available

Empowered With Movement to Prevent Obesity and Weight Regain

NCT02923674
View directory record Official record
Conditions
Obesity, Weight Loss, Sedentary Lifestyle
Interventions
Weight loss, Exercise, Sitless
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 85 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 28, 2026, 6:35 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
Interventions
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men

NCT00696618
View directory record Official record
Conditions
HIV Infections
Interventions
Fleet Enema, tap water enema, Normosol-R enema
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 28, 2026, 6:35 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

NCT07775313
View directory record Official record
Conditions
WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
Interventions
Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

NCT03020160
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Sacramento, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 28, 2026, 6:35 PM EDT